PMS-ZOLMITRIPTAN ODT TABLET (ORALLY DISINTEGRATING)
Nchi: Kanada
Lugha: Kiingereza
Chanzo: Health Canada
Tabia za bidhaa
(SPC)
15-04-2020
Hati zingine za bidhaa hii hazipatikani kwa sasa, unaweza kutuma ombi kwa huduma ya wateja wetu na tutakuarifu mara tu tutakapopata.
Tuma ombi.
Tuma ombi.
Viambatanisho vya kazi:
ZOLMITRIPTAN
Inapatikana kutoka:
PHARMASCIENCE INC
ATC kanuni:
N02CC03
INN (Jina la Kimataifa):
ZOLMITRIPTAN
Kipimo:
2.5MG
Dawa fomu:
TABLET (ORALLY DISINTEGRATING)
Tungo:
ZOLMITRIPTAN 2.5MG
Njia ya uendeshaji:
ORAL
Vitengo katika mfuko:
6/30
Dawa ya aina:
Prescription
Eneo la matibabu:
SELECTIVE SEROTONIN AGONISTS
Bidhaa muhtasari:
Active ingredient group (AIG) number: 0134381001; AHFS:
Idhini hali ya:
APPROVED
Idhini ya tarehe:
2011-06-07
Tabia za bidhaa
PRODUCT MONOGRAPH
PR
PMS-ZOLMITRIPTAN
Zolmitriptan Film-Coated Tablets, House Standard
2.5 mg
PR
PMS-ZOLMITRIPTAN ODT
Zolmitriptan Orally Dispersible Tablets, House Standard
2.5 mg
5-HT1 RECEPTOR AGONIST
MIGRAINE THERAPY
PHARMASCIENCE INC.
6111 Royalmount Ave., Suite 100
Montréal, Québec
H4P 2T4
www.pharmascience.com
DATE OF REVISION:
April 15, 2020
Submission Control No.: 237071
_ _
_pms-ZOLMITRIPTAN and pms-ZOLMITRIPTAN ODT Product Monograph _
_Page 2 of 41 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................5
ADVERSE REACTIONS
..................................................................................................12
DRUG INTERACTIONS
..................................................................................................18
DOSAGE AND ADMINISTRATION
..............................................................................20
OVERDOSAGE
................................................................................................................21
ACTION AND CLINICAL PHARMACOLOGY
............................................................22
STORAGE AND STABILITY
..........................................................................................25
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................25
PART II: SCIENTIFIC INFORMATION
...............................................................................26
PHARMACEUTICAL INFORMATION
..........................................................................26
CLINICAL TRIALS
....................
Soma hati kamili
